IMS Health set to close oversubscribed
Commitments are flooding in on the $2bn financing backing the buy-out of IMS Health, the pharmaceutical intelligence provider. The financing, which is expected to have a $750m equivalent euro carve-out, will close 1.25 to 1.5 times oversubscribed, according to market participants. The commitment deadline is this Monday, February 15.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast
